AbbVie suing Amgen over Humira biosimilar

AbbVie Inc. (NYSE:ABBV) filed suit against Amgen Inc. (NASDAQ:AMGN) in the U.S. District Court for the District of Delaware alleging that Amgen's ABP 501, a biosimilar version of AbbVie's Humira adalimumab, infringes 10 patents covering Humira.

AbbVie is seeking an injunction to prevent Amgen from launching ABP 501. Once Amgen provides 180-day notice that it plans to market the biosimilar, AbbVie said it plans to assert another 51 patents it believes Amgen infringes. ...